Nasdaq

Myriad Genetics Study Shows Increased Completion Rates for Hereditary Cancer Testing Through Online Screening and Education Tools

Myriad Genetics, Inc. announced a study indicating that the use of its online screening tool, MyGeneHistory®, alongside a virtual education program, significantly increased the completion rates for ...
Cure Today

23andMe, Advocacy Organizations Partner on Lung Cancer Genetics Study

23andMe and 20 lung cancer advocacy organizations are working to improve lung cancer detection, risk reduction and care. 23andMe, the genetic health and biopharmaceutical company, has partnered with ...
Business Insider

Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology

SALT LAKE CITY, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed ...
Business Wire

Ambry Genetics Publishes 43,000 Patient Study Showing Combined RNA and DNA Analysis Identifies Patients Who Are High-Risk for Cancer but Would Have Been Missed by DNA Testing Alone

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical diagnostic testing and a subsidiary of REALM IDx, Inc., announced today the findings of a study that showed paired RNA and ...
Nasdaq

Myriad Genetics' RiskScore® Study Shows Impact on Breast Cancer Screening Recommendations Based on Individual Patient Risk

Myriad Genetics, Inc. announced in a press release that a study published in JCO Precision Oncology indicates their RiskScore® tool enhances breast cancer screening by aligning clinician ...
Seeking Alpha

Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology

SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision ...